Niagen Bioscience Launches NB4168 Pharmaceutical Program Targeting Rare Genetic Diseases and Accelerated Aging
Niagen Bioscience expands its leadership in NAD+ science into pharmaceutical development with NB4168, an investigational oral therapy designed for Ataxia Telangiectasia and other DNA repair disorders.
Niagen Bioscience, Inc. has officially entered the pharmaceutical development arena with the launch of its first investigational drug candidate, NB4168, marking a significant strategic milestone for the company. Developed through its wholly owned subsidiary, NAD Pharmaceuticals Corp., the program is focused on creating novel therapies for accelerated aging disorders and rare genetic diseases where defects in DNA repair and mitochondrial function play a central role.
The announcement signals an important evolution for Niagen Bioscience, a company widely recognized for its leadership in NAD+ (nicotinamide adenine dinucleotide) science. While the organization has built its reputation through nutritional ingredients and healthy aging products centered around nicotinamide riboside (NR), the launch of NB4168 represents a transition into regulated pharmaceutical research aimed at treating serious medical conditions with significant unmet clinical needs.
NB4168 is a proprietary derivative of nicotinamide riboside developed specifically for pharmaceutical applications. The company’s initial development efforts will focus on Ataxia Telangiectasia (A-T), a rare and devastating inherited disease for which there are currently no U.S. Food and Drug Administration (FDA)-approved treatments.
Expanding NAD+ Science Beyond Nutritional Health
For years, Niagen Bioscience has invested heavily in research exploring the biological importance of NAD+, an essential coenzyme involved in numerous cellular processes. NAD+ plays a critical role in energy metabolism, mitochondrial performance, DNA repair, cellular signaling, and responses to oxidative and metabolic stress.
Declining NAD+ levels have been associated with aging and multiple disease processes. Consequently, researchers worldwide have investigated strategies to restore or maintain NAD+ concentrations using precursor molecules such as nicotinamide riboside.
The company’s pharmaceutical initiative aims to apply these scientific insights to diseases driven by impaired DNA repair pathways and mitochondrial dysfunction. Many rare inherited disorders exhibit these underlying biological defects, making NAD+ modulation a promising therapeutic strategy.
According to Niagen Bioscience, the pharmaceutical platform will initially prioritize rare pediatric diseases before potentially expanding into additional conditions linked to accelerated aging and defective DNA repair mechanisms.
NB4168 Designed Specifically as a Drug Candidate
Unlike commercially available nicotinamide riboside supplements, NB4168 has been engineered as a proprietary pharmaceutical molecule intended exclusively for prescription drug development.
The investigational compound has been designed for oral administration and incorporates modifications intended to deliver significantly higher systemic exposure to nicotinamide riboside after dosing.
Following absorption into the bloodstream, nicotinamide riboside enters cells directly and is converted into NAD+ through the nicotinamide riboside kinase pathway. By increasing intracellular NAD+ availability, researchers hope to improve cellular energy production while supporting DNA repair mechanisms that are compromised in certain genetic diseases.
Niagen Bioscience emphasized that NB4168 is neither an approved medication nor a dietary supplement currently available to consumers. Instead, it remains an investigational pharmaceutical candidate protected under the company’s expanding intellectual property portfolio, including composition-of-matter patents designed to safeguard its proprietary molecular design.
Initial Focus on Ataxia Telangiectasia
The first indication selected for NB4168 is Ataxia Telangiectasia (A-T), a rare inherited neurodegenerative disorder caused by mutations in the ATM gene.
The ATM protein serves as one of the body’s most important regulators of DNA damage repair. When mutations disable this protein, cells lose their ability to effectively repair damaged DNA, resulting in progressive neurological decline and widespread systemic complications.
Children diagnosed with A-T typically begin showing symptoms during early childhood. One of the earliest clinical signs is worsening loss of balance and motor coordination, which progressively affects walking, movement, and daily activities.
As the disease advances, patients frequently develop:
- Progressive neurological impairment
- Loss of motor coordination
- Immune system dysfunction
- Increased susceptibility to recurrent infections
- Chronic pulmonary complications
- Elevated lifetime cancer risk
- Increasing dependence on mobility assistance, including wheelchairs
Because the disease affects multiple organ systems simultaneously, patient management is generally limited to supportive therapies rather than treatments that address the underlying genetic defect.
Currently, there are no FDA-approved therapies specifically indicated for Ataxia Telangiectasia.
Although considered an ultra-rare disease, A-T has a profound impact on affected families. Published estimates suggest the disorder affects approximately one in 40,000 individuals in the United States and roughly one in 150,000 people across Europe.
Clinical Research Provides Scientific Foundation
Niagen Bioscience believes NB4168 enters development supported by an encouraging body of existing scientific literature surrounding nicotinamide riboside.
Chief Executive Officer Rob Fried noted that two independently conducted published clinical studies have investigated nicotinamide riboside in patients with Ataxia Telangiectasia. According to the company, both studies demonstrated statistically significant improvements across evaluated clinical measures.
In addition to those clinical investigations, multiple preclinical studies have explored NR supplementation in disease models relevant to A-T.
Although these earlier studies did not evaluate NB4168 itself, they provide important scientific rationale supporting continued pharmaceutical development.
The company believes the existing research substantially reduces scientific uncertainty surrounding the therapeutic potential of increasing NAD+ levels in diseases characterized by defective DNA repair.
Improved Pharmacokinetic Performance
One distinguishing feature of NB4168 is its pharmacokinetic profile.
According to Niagen Bioscience, nonclinical pharmacokinetic studies completed thus far have demonstrated substantially higher bloodstream exposure to the active nicotinamide riboside component compared with conventional NR chloride formulations.
Greater systemic exposure could potentially translate into improved intracellular delivery of nicotinamide riboside and more effective elevation of NAD+ concentrations in target tissues.
Enhanced bioavailability is considered an important objective in pharmaceutical development because it may improve dosing efficiency while maximizing therapeutic activity.
These findings support continued investigation of NB4168 as a pharmaceutical candidate distinct from existing nutritional formulations.
Scientific Evidence Extends Beyond A-T
Research supporting NAD+ biology extends beyond Ataxia Telangiectasia.
Multiple published studies have explored nicotinamide riboside and NAD+ augmentation in several additional disorders involving impaired DNA repair and accelerated aging.
These include:
- Werner syndrome
- Cockayne syndrome
- Xeroderma pigmentosum group A
Each of these rare inherited conditions involves defects in cellular maintenance pathways that contribute to premature aging, neurological dysfunction, and progressive tissue degeneration.
Although none of these studies involved NB4168 directly, they collectively strengthen the scientific hypothesis that enhancing NAD+ metabolism may provide therapeutic benefits across multiple rare genetic disorders.
Niagen Bioscience emphasized that these previous investigations were exploratory rather than registrational clinical trials. Nevertheless, they contribute valuable biological evidence supporting continued pharmaceutical research.
Stage-Gated Drug Development Strategy
The company intends to advance NB4168 through a structured, evidence-based development program.
According to Andrew Shao, Ph.D., Senior Vice President of Global Scientific & Regulatory Affairs, the program has been designed around clearly defined scientific milestones.
Initial development activities will include:
- Expanded pharmacological characterization
- Toxicology evaluations
- Pharmacokinetic assessments
- Pharmacodynamic analyses
- Preparation for future clinical studies
Each stage will generate evidence necessary to determine whether NB4168 demonstrates sufficient safety and biological activity to justify advancement into larger clinical development programs.
The company stated that its long-term objective is to determine whether the investigational therapy can ultimately provide meaningful clinical benefit for patients living with rare pediatric diseases.
Strong Intellectual Property Position
Niagen Bioscience enters pharmaceutical development with an extensive intellectual property portfolio built around NAD+ precursor technologies.
The company reports holding more than 50 patents protecting nicotinamide riboside and related NAD+ precursor innovations.
NB4168 is covered by robust patent protection, including composition-of-matter claims that provide exclusivity over the proprietary molecular structure itself.
Such intellectual property protection is particularly important within pharmaceutical development, where lengthy clinical programs and regulatory review require substantial long-term investment.
Strategic Evolution for Niagen Bioscience
The launch of NB4168 reflects a broader transformation in Niagen Bioscience’s corporate strategy.
Historically known for commercializing nutritional products such as Niagen®, Tru Niagen®, and Niagen™ Plus, the company is now leveraging decades of NAD+ research to pursue prescription medicines targeting severe diseases with limited therapeutic options.
By establishing NAD Pharmaceuticals Corp. as a dedicated pharmaceutical subsidiary, the company is creating a separate platform focused exclusively on regulated drug development while continuing its existing consumer health business.
If successful, NB4168 could become the first pharmaceutical product emerging from Niagen Bioscience’s broader NAD+ research platform.
The formal introduction of NB4168 represents the beginning of what Niagen Bioscience envisions as a long-term pharmaceutical pipeline focused on rare diseases associated with DNA repair deficiencies and accelerated aging biology.
With encouraging published research supporting nicotinamide riboside, promising early pharmacokinetic findings, strong patent protection, and an initial focus on the significant unmet medical need represented by Ataxia Telangiectasia, the company is positioning itself to expand beyond nutritional science into therapeutic drug development.
As preclinical studies continue and future clinical investigations progress, NB4168 will serve as the flagship candidate for Niagen Bioscience’s pharmaceutical ambitions, potentially opening new treatment possibilities for patients affected by rare genetic disorders where effective therapies remain unavailable today.
About Niagen Bioscience
Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.
At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com).
Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated molecule.